

ring nodes :

1 2 3 4 5 6 7 8 9 10

ring bonds :

1-2 1-7 2-3 3-4 4-5 5-6 6-7 6-8 7-10 8-9 9-10

exact/norm bonds :

1-2 1-7 2-3 3-4 4-5 5-6 6-7 6-8 7-10 8-9 9-10

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

10/531,111

=> d his

(FILE 'HOME' ENTERED AT 12:06:04 ON 09 NOV 2007)

FILE 'REGISTRY' ENTERED AT 12:06:46 ON 09 NOV 2007

L1 STRUCTURE UPLOADED
L2 6 S L1
L3 210 S L1 SSS FUL
L4 147 S L3 AND CAPLUS/LC
L5 63 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 12:07:42 ON 09 NOV 2007

L6 65 S L3

FILE 'REGISTRY' ENTERED AT 12:08:20 ON 09 NOV 2007

L7 22 S L3 AND NRS>2
L8 188 S L3 NOT L7
L9 147 S L3 AND NRS=1
L10 63 S L3 NOT L9
L11 86147 S 5-7/SZ
L12 51 S L3 AND L11

FILE 'CAPLUS' ENTERED AT 12:10:12 ON 09 NOV 2007

L13 14 S L12

=> d ibib abs hitstr total

☒ 3 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:230727 CAPLUS
 DOCUMENT NUMBER: 146:295914
 TITLE: Preparation of pyrazolones as 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitors for treatment of diabetes, dyslipidemia, obesity, and hypertension
 INVENTOR(S): Amrein, Kurt; Hunziker, Daniel; Kuhn, Bernd; Mayweg, Alexander V.; Neidhart, Werner
 PATENT ASSIGNEE(S): Switz.
 SOURCE: U.S. Pat. Appl. Publ., 38pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007049574	A1	20070301	US 2006-511542	20060829
WO 2007025880	A2	20070308	WO 2006-EP65471	20060821
WO 2007025880	A3	20070503		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2005-107970 A 20050831
 OTHER SOURCE(S): MARPAT 146:295914
 GI



AB Title compds. [I; R1 = H, alkyl, cycloalkyl, aralkyl, haloalkyl, aryl, cycloalkylalkyl, pyridylmethyl, heterocyclyl; R2 = H, alkyl, cycloalkyl, aryl, aralkyl, benzothiazolyl, (substituted) bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl; R1R2 = atoms to form pyrazolidine, hexahydropyridazine, etc.; R1R4 = (CH2)m; R3R4 = (CH2)n; m, n = 3-6; R3 = cyclopropyl, arylcyclopropyl, iso-Pr, tert-Bu, adamantyl,

bicyclo[2.2.2]octyl; with provisos], were prepared Thus, Me 3-cyclopropyl-3-oxopropionate and PhNHNH2 were heated together in HOAc at 120° overnight to give 5-cyclopropyl-2-phenyl-2,4-dihydropyrazol-3-one. This was heated in a bomb with MeI at 100° for 2 days to give 5-cyclopropyl-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one. The latter was stirred with NBS in CH2Cl2 for 24 h to give 4-bromo-5-cyclopropyl-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one. This was heated with cyclopropylboronic acid, K3PO4, tricyclohexylphosphine, Pd (OAc)2, H2O, and PhMe at 100° for 4 days to give 4,5-dicyclopropyl-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one. The latter inhibited 11 β -HSD1 with IC50 = 21 nM.


IT 927900-14-9P 927900-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrazolones as 11 β -HSD1 inhibitors for treatment of diabetes, dyslipidemia, obesity, and hypertension)


RN 927900-14-9 CAPLUS

CN 1H-Pyrazolo[1,5-a]azepin-2(4H)-one, 5,6,7,8-tetrahydro-3-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (CA INDEX NAME)



RN 927900-15-0 CAPLUS

CN 1H-Pyrazolo[1,5-a]azepin-2(4H)-one, 5,6,7,8-tetrahydro-1-methyl-3-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (CA INDEX NAME)



IT 927900-93-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolones as 11 β -HSD1 inhibitors for treatment of diabetes, dyslipidemia, obesity, and hypertension)

RN 927900-93-4 CAPLUS

CN 1H-Pyrazolo[1,5-a]azepin-2(4H)-one, 5,6,7,8-tetrahydro- (CA INDEX NAME)



10/531,111



B
q
q
m
j
d
b
o
u
t

L13 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:467894 CAPLUS
 DOCUMENT NUMBER: 141:38607
 TITLE: Preparation of novel pyrazoloazepines as transforming
 growth factor- β (TGF- β) signal transduction
 inhibitors for use in pharmaceutical compositions
 INVENTOR(S): Sawyer, Jason Scott
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048381	A2	20040610	WO 2003-US32746	20031110
WO 2004048381	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003291642	A1	20040618	AU 2003-291642	20031110
EP 1578749	A2	20050928	EP 2003-768530	20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006079680	A1	20060413	US 2005-531111	20050413
PRIORITY APPLN. INFO.:			US 2002-428892P	P 20021122
			WO 2003-US32746	W 20031110
OTHER SOURCE(S):		MARPAT 141:38607		
GI				



AB Pyrazoloazepines, such as I [R = H, OMe, OH, 2-(morpholin-4-yl)ethyloxy],

were prepared for therapeutic use treatment of fibroproliferative diseases associated with TGF- β 1 over production. Thus, pyrazoloazepine I (R = H) was prepared via N-acylation of (1-pyridin-2-yl-2-quinolin-4-ylethylidene)hydrazine with 6-chlorohexanoyl chloride using pyridine in CH₂Cl₂ to give intermediate hydrazide II with 100% yield and subsequent intramol. cyclocondensation by treating the hydrazide using NaH in DMF followed by quenching with aqueous ammonium chloride to form the desired pyrazoloazepine I (R = H) in 21% yield for the cyclocondensation step. Pharmaceutical formulations containing the prepared pyrazoloazepines were discussed.


IT 701295-44-5P 701295-47-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazoloazepines as transforming growth factor- β (TGF- β) signal transduction inhibitors for use in pharmaceutical compns.)


RN 701295-44-5 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine, 5,6,7,8-tetrahydro-3-(7-methoxy-4-quinolinyl)-2-(2-pyridinyl)- (CA INDEX NAME)



RN 701295-47-8 CAPLUS

CN 7-Quinolinol, 4-[5,6,7,8-tetrahydro-2-(2-pyridinyl)-4H-pyrazolo[1,5-a]azepin-3-yl]- (CA INDEX NAME)



IT 701295-42-3P 701295-48-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazoloazepines as transforming growth factor- β (TGF- β) signal transduction inhibitors for use in pharmaceutical compns.)

RN 701295-42-3 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine, 5,6,7,8-tetrahydro-2-(2-pyridinyl)-3-(4-


10/531,111

quinolinyl)- (CA INDEX NAME)



RN 701295-48-9 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine, 5,6,7,8-tetrahydro-3-[7-[2-(4-morpholinyl)ethoxy]-4-quinolinyl]-2-(2-pyridinyl)- (CA INDEX NAME)



☒ L13 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:376819 CAPLUS

DOCUMENT NUMBER: 138:385173

TITLE: Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease

INVENTOR(S): Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SOURCE: PCT Int. Appl., 1243 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040096	A2	20030515	WO 2002-US36072	20021108
WO 2003040096	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2466284	A1	20030515	CA 2002-2466284	20021108
WO 2003040096	A2	20030515	WO 2002-XA36072	20021108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002359376	A1	20030519	AU 2002-359376	20021108
US 2004171881	A1	20040902	US 2002-291318	20021108
US 7176242	B2	20070213		
EP 1453789	A2	20040908	EP 2002-793909	20021108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014035	A	20050426	BR 2002-14035	20021108
JP 2005520791	T	20050714	JP 2003-542142	20021108
CN 1759095	A	20060412	CN 2002-826786	20021108
NZ 533107	A	20070427	NZ 2002-533107	20021108
MX 2004PA04428	A	20040910	MX 2004-PA4428	20040507
ZA 2004003578	A	20051010	ZA 2004-3578	20040511
IN 2004KN00627	A	20060224	IN 2004-KN627	20040514



10/531,111

NO 2004002359
US 2007213316
PRIORITY APPLN. INFO.:

A 20040806
A1 20070913

NO 2004-2359 20040607
US 2006-636903 20061211
US 2001-337122P P 20011108
US 2001-344086P P 20011228
US 2002-345635P P 20020103
US 2002-291318 A3 20021108
WO 2002-US36072 W 20021108

OTHER SOURCE(S): MARPAT 138:385173
GI



- AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R3 = H, alkyl, haloalkyl, alkenyl, etc.; or R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO₂, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxyalkyl, etc.; R5 = R₆X (wherein X = CO, SO₂, (un)substituted CH₂; R₆ = (un)substituted Ph, naphthyl, indanyl, etc.); R₂₅ = H, alkyl, alkoxy, etc.] which have activity as inhibitors of β -secretase and are therefore useful in treating a variety of disorders such as Alzheimer's disease, were prepared E.g., a multi-step synthesis of (1S,2R)-II, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-(3,5-difluorophenyl)propanoic acid, was given. The compds. I showed IC₅₀ of < 20 μ M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.
- IT 527722-06-1P 527725-61-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating


10/531,111

Alzheimer's disease)

RN 527722-06-1 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-3-carboxamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 527725-61-7 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-3-carboxamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[3-ethylphenyl)methyl]amino]-2-hydroxypropyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



Y L13 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:714162 CAPLUS
 DOCUMENT NUMBER: 137:232664
 TITLE: Preparation of pyrazolopyrimidines as inhibitors of
 guanosine 3',5'-monophosphate phosphodiesterases (cGMP
 PDEs).
 INVENTOR(S): Barber, Christopher Gordon; Maw, Graham Nigel
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: Eur. Pat. Appl., 96 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1241170	A2	20020918	EP 2002-251367	20020227
EP 1241170	A3	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002193388	A1	20021219	US 2002-93105	20020306
US 6831074	B2	20041214		
JP 2002322180	A	20021108	JP 2002-68015	20020313
CA 2376844	A1	20020916	CA 2002-2376844	20020314
MX 2002PA02945	A	20040716	MX 2002-PA2945	20020315
BR 2002000843	A	20030325	BR 2002-843	20020318
US 2005107412	A1	20050519	US 2004-970715	20041020
PRIORITY APPLN. INFO.:			GB 2001-6631	A 20010316
			US 2001-290734P	P 20010514
			US 2002-93105	A3 20020306

OTHER SOURCE(S): MARPAT 137:232664
 GI



AB Title compds. [I; Q = (substituted) fused pyrazolo; A = SO₂, CO, CH(OH); V = O, NR₅; X = CH, N; R₃-R₅ = H, alkyl, cycloalkyl, (substituted) heterocyclyl, aryl, etc.], were prepared e.g. for treatment of mammalian sexual disorders (no data). Thus, potassium bis(trimethylsilyl)amide was added to a solution of 3-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxamide (preparation given) in ethanol and the reaction mixture heated in a

sealed vessel at 130° for 16 h to give 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3,7,8,9-tetrahydro-4H-pyrrolo(2',1':5,1)pyrazolo[4,3-d]pyrimidin-4-one.


IT 459157-17-6P 459157-21-2P 459157-23-4P
459157-25-6P 459157-27-8P 459157-28-9P
459157-29-0P 459157-30-3P 459157-31-4P
459157-36-9P 459157-37-0P 459157-41-6P
459157-42-7P 459157-49-4P 459157-50-7P
459157-56-3P 459157-57-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as inhibitors of guanosine 3',5'-monophosphate phosphodiesterases)


RN 459157-17-6 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2,5-dicarboxylic acid, 5,6,7,8-tetrahydro-4-oxo-, diethyl ester (9CI) (CA INDEX NAME)




RN 459157-21-2 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-oxo- (CA INDEX NAME)



RN 459157-23-4 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-oxo-, ethyl ester (CA INDEX NAME)



10/531,111


RN 459157-25-6 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-methylene-, ethyl ester (CA INDEX NAME)




RN 459157-27-8 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-methyl-, ethyl ester (CA INDEX NAME)



RN 459157-28-9 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-hydroxy-, ethyl ester (CA INDEX NAME)



RN 459157-29-0 CAPLUS


CN 6H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 7,8-dihydro-, ethyl ester (CA INDEX NAME)

10/531,111




RN 459157-30-3 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-, ethyl ester (CA INDEX NAME)




RN 459157-31-4 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-methyl- (CA INDEX NAME)



RN 459157-36-9 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-3-nitro- (CA INDEX NAME)



RN 459157-37-0 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-4-methyl-3-nitro- (CA INDEX NAME)

10/531,111




RN 459157-41-6 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 5,6,7,8-tetrahydro-3-nitro- (CA INDEX NAME)




RN 459157-42-7 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 5,6,7,8-tetrahydro-4-methyl-3-nitro- (CA INDEX NAME)



RN 459157-49-4 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 3-amino-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 459157-50-7 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 3-amino-5,6,7,8-tetrahydro-4-methyl- (CA INDEX NAME)

10/531,111



RN 459157-56-3 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 3-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 459157-57-4 CAPLUS

CN 4H-Pyrazolo[1,5-a]azepine-2-carboxamide, 3-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-5,6,7,8-tetrahydro-4-methyl- (CA INDEX NAME)

10/531,111




[Y] L13 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:379222 CAPLUS
 DOCUMENT NUMBER: 137:232795
 TITLE: Radical cyclisation onto pyrazoles: synthesis of withasomnine
 AUTHOR(S): Allin, Steven M.; Barton, William R. S.; Bowman, W. Russell; McInally, Tom
 CORPORATE SOURCE: Department of Chemistry, Loughborough University, Loughborough, LE11 3TU, UK
 SOURCE: Tetrahedron Letters (2002), 43(23), 4191-4193
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:232795
 AB A novel synthetic protocol for the synthesis of [1,2-b]-fused bicyclic pyrazoles has been developed using radical cyclization. The protocol uses cyclisation of pyrazole-1-(ω -alkyl) radicals generated from 1-(ω -(phenylselenenyl)alkyl)-pyrazole precursors. The pyrazole natural product, withasomnine (3-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole), and larger ring analogs have been synthesized in good yield using the protocol. A Bu₃SnH-mediated oxidative cyclisation mechanism is facilitated by azo or Et₃B radical initiators acting as oxidants of the intermediate π -radicals.
 IT 457925-34-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of withasomnine and other [1,2-b]-fused bicyclic pyrazoles via a radical cyclization onto pyrazoles)
 RN 457925-34-7 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepine, 5,6,7,8-tetrahydro-3-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

[Y] L13 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:576880 CAPLUS
 DOCUMENT NUMBER: 127:293165
 TITLE: Novel Parham-type cycloacylations of
 1H-pyrazole-1-alkanoic acids
 AUTHOR(S): Larsen, Scott D.
 CORPORATE SOURCE: Discovery Chemistry Research Pharmacia Upjohn, Inc.,
 Kalamazoo, MI, 49001, USA
 SOURCE: Synlett (1997), (8), 1013-1014
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Thieme
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:293165
 AB Exposure of 1H-pyrazole-1-alkanoates to 2 equiv BuLi affords the
 corresponding cyclic ketones via a Parham-type cyclization process.
 Although yields are modest, this procedure represents a simple and direct
 intramol. acylation of a non-nucleophilic pyrazole carbon.
 IT 197094-20-5P 197094-21-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Parham-type cycloacylation of pyrazolealkanoic acids)
 RN 197094-20-5 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepin-4-one, 5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 197094-21-6 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepin-4-one, 5,6,7,8-tetrahydro-2-(4-methylphenyl)-
 (CA INDEX NAME)



[Y] L13 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:637683 CAPLUS
 DOCUMENT NUMBER: 125:300999
 TITLE: Pyridino substituted oximes useful as
 anti-atherosclerosis and anti-hypercholesterolemic
 agents
 INVENTOR(S): Larsen, Scott D.; Spilman, Charles H.
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: U.S., 19 pp. Cont.-in-part of U.S. Ser. No. 900, 229,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5565468	A	19961015	US 1994-313684	19940927
AT 177426	T	19990315	AT 1993-912362	19930505
ES 2130269	T3	19990701	ES 1993-912362	19930505
CN 1081678	A	19940209	CN 1993-107183	19930617
US 5523318	A	19960604	US 1995-466181	19950606
US 5597816	A	19970128	US 1995-468158	19950606
PRIORITY APPLN. INFO.:			US 1992-900229	B2 19920617
			US 1994-313684	A3 19940927
OTHER SOURCE(S):		CASREACT 125:300999; MARPAT 125:300999		
GI				



- AB Imidazopyridino- and pyrazolopyridino- substituted oximes are disclosed for the treatment of atherosclerosis and hypercholesterolemia. Thus, 2,4-pentanedione mono(1-aminotetrahydroazepinyl)hydrazone was cyclized to the ketone I [X = O] which was converted to the oxime I [X = NOH] as a mixture of isomers. In quail I [X = NOH] at 50 mg/kg day for 7 days in the diet gave a LDL+VLDL level 56% of controls.
- IT 154877-22-2P 154877-69-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of oximes of condensed pyridines as anticholesteremics)
- RN 154877-22-2 CAPLUS
- CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/531,111



RN 154877-69-7 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 154877-24-4P 154877-26-6P 154877-36-8P

154877-73-3P 183116-84-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oximes of condensed pyridines as anticholesteremics)


RN 154877-24-4 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, O-acetyloxime (9CI) (CA INDEX NAME)



RN 154877-26-6 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, O-(2-hydroxyethyl)oxime (9CI) (CA INDEX NAME)




10/531,111

RN 154877-36-8 CAPLUS

CN Ethanone, 2-(phenylthio)-1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 154877-73-3 CAPLUS


CN Ethanone, 2-(phenylthio)-1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 183116-84-9 CAPLUS

CN 1-Propanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime (CA INDEX NAME)




IT 154877-55-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oximes of condensed pyridines as anticholesteremics)


RN 154877-55-1 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)- (9CI) (CA INDEX NAME)

10/531,111



Y L13 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:718522 CAPLUS
 DOCUMENT NUMBER: 123:339867
 TITLE: Formation of a novel 1:2 adduct by reaction of
 3a,6a-diazapentalene with dimethyl
 acetylenedicarboxylate
 AUTHOR(S): Matsumoto, Kiyoshi; Iida, Hirokazu; Hinomoto, Tetsu;
 Uchida, Takane
 CORPORATE SOURCE: Graduate Sch. of Human and Environmental Studies,
 Kyoto Univ., Kyoto, 606-01, Japan
 SOURCE: Journal of Chemical Research, Synopses (1995), (8),
 338-9
 CODEN: JRPSDC; ISSN: 0308-2342
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 123:339867
 AB Reaction of the parent 3a,6a-diazapentalene with di-Me
 acetylenedicarboxylate afforded a 1:2 adduct, the pyrazolo[1,5-a]azepine
 system, whose novel structure was deduced based upon the mol. composition and
 the 1H and 13C NMR and 1H-13C 2D NMR spectra data.
 IT 170464-98-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (reaction of 3a,6a-diazapentalene with di-Me acetylenedicarboxylate)
 RN 170464-98-9 CAPLUS
 CN 1H-Pyrazolo[1,5-a]azepine-4,5-dicarboxylic acid, 1-[3-methoxy-1-
 (methoxycarbonyl)-3-oxo-1-propenyl]-, dimethyl ester (9CI) (CA INDEX
 NAME)



Y L13 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:508609 CAPLUS
 DOCUMENT NUMBER: 121:108609
 TITLE: On the reaction of 1-aza-2-azoniaallene salts with acetylenes
 AUTHOR(S): Wang, Quanrui; Al-Talib, Mahmoud; Jochims, Johannes C.
 CORPORATE SOURCE: Fak. Chem., Univ. Konstanz, Konstanz, D-78434, Germany
 SOURCE: Chemische Berichte (1994), 127(3), 541-7
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:108609
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 1-Aza-2-azoniaallene cations, prepared in situ from geminal chloro(alkylazo) compds., react with acetylenes to give either 1H-pyrazolium salts, e.g. I, or 4H-pyrazolium salts, e.g. II, or mixts. of both. 4H-Pyrazolium salts with a hydrogen atom attached to C(4) rearrange to the protonated 1H-pyrazoles, e.g. III, from which the free bases are obtained upon treatment with aqueous NaOH. According to AM1 calcns. the cycloaddn. of acetylenes to 1-aza-2-azoniaallene cations is a concerted process, which can be classified as a 1,3-dipolar cycloaddn. with reverse electron demand. The cycloaddn. forming the intermediates is followed by an [1,2] alkyl shift to furnish the final products. The direction of the [1,2] shift has been governed by subtle steric effects.

IT 156894-21-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 156894-21-2 CAPLUS

CN Pyrazolo[1,5-a]azepin-9-ium, 2-butyl-1,4,5,6,7,8-hexahydro-1-(2,4,6-trichlorophenyl)-, (T-4)-tetrachloroaluminate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 156894-20-1

CMF C18 H22 Cl3 N2




10/531,111

CM 2

CRN 17611-22-2


CMF Al Cl4

CCI CCS



[Y] L13 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:323567 CAPLUS
 DOCUMENT NUMBER: 120:323567
 TITLE: Preparation of (hydroximinoalkyl)diazoles as
 anticholesteremics
 INVENTOR(S): Larsen, Scott D.; Spilman, Charles H.
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325553	A1	19931223	WO 1993-US4059	19930505
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9342933	A	19940104	AU 1993-42933	19930505
EP 649425	A1	19950426	EP 1993-912362	19930505
EP 649425	B1	19990310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07507796	T	19950831	JP 1993-501458	19930505
AT 177426	T	19990315	AT 1993-912362	19930505
ES 2130269	T3	19990701	ES 1993-912362	19930505
CN 1081678	A	19940209	CN 1993-107183	19930617
PRIORITY APPLN. INFO.:			US 1992-900229	A2 19920617
			WO 1993-US4059	A 19930505
OTHER SOURCE(S):		MARPAT 120:323567		
GI				



AB RR2C:NR1 [R = e.g. (substituted)pyrazolo[1,5-a]pyridin-3-yl, etc.; R1 = OH, hydroxyalkoxy, alkanoyloxy, etc.; R2 = alkyl, (substituted)Ph, etc.] were prepared. Thus, imidazopyridinylethanone I (X = O) was condensed with HONH₂.HCl to give I (X = NOH) which gave LDL+VLDL serum cholesterol level 41% that of controls in chow-fed quail receiving 50mg/kg from feed.


IT 154877-55-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of anticholesteremic)

RN 154877-55-1 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-

10/531,111

(9CI) (CA INDEX NAME)




IT 154877-69-7P 154877-73-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 154877-69-7 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 154877-73-3 CAPLUS

CN Ethanone, 2-(phenylthio)-1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 154877-22-2P 154877-24-4P 154877-26-6P

154877-36-8P 154877-39-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticholesteremic)

RN 154877-22-2 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/531,111




RN 154877-24-4 CAPLUS

CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, O-acetyloxime (9CI) (CA INDEX NAME)



RN 154877-26-6 CAPLUS


CN Ethanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, O-(2-hydroxyethyl)oxime (9CI) (CA INDEX NAME)



RN 154877-36-8 CAPLUS

CN Ethanone, 2-(phenylthio)-1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, oxime, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 154877-39-1 CAPLUS

CN 1-Propanone, 1-(5,6,7,8-tetrahydro-2-methyl-4H-pyrazolo[1,5-a]azepin-3-yl)-, O-acetyloxime (9CI) (CA INDEX NAME)


10/531,111




Y L13 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1976:577307 CAPLUS
 DOCUMENT NUMBER: 85:177307
 TITLE: Spontaneous transpositions from pyrazolenines into pyrazoles. Competitive [1,5] migrations of an acyl or carbalkoxy group to the carbon and nitrogen
 AUTHOR(S): Franck-Neumann, Michel; Dietrich-Buchecker, Christiane
 CORPORATE SOURCE: Inst. Chim., Univ. Louis Pasteur, Strasbourg, Fr.
 SOURCE: Tetrahedron Letters (1976), (24), 2069-72
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 85:177307
 GI For diagram(s), see printed CA Issue.
 AB In the thermal rearrangement of pyrazolenines, prepared from diazo ketones or esters with acetylenes, the acyl or alkoxycarbonyl group migrated competitively to C-4 and N-2. E.g., MeC(:N2)C(=O)Me with MeCOC.tplbond.CH gave the pyrazolenine I which underwent [1,5]-migrations to give II and III in a ratio 1:4. An alkoxycarbonyl group migrates more easily to C than an acyl group, the pyrazolenines with an alkoxycarbonyl in the 3 position being more stable than those with an acyl group in the same position. An acyl group in position 5 makes this migration more facile than do alkoxycarbonyl or cyano substituents.
 IT 55300-04-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55300-04-4 CAPLUS
 CN 8H-Pyrazolo[1,5-a]azepin-8-one, 2-acetyl-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



[Y] L13 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1975:57601 CAPLUS
 DOCUMENT NUMBER: 82:57601
 TITLE: Diazo compounds and azides. XXI. Sigmatropic
 (1,5)-acyl shifts in the cycloaddition of
 2-diazocycloalkanones to activated acetylenes
 AUTHOR(S): Martin, Michael; Regitz, Manfred
 CORPORATE SOURCE: Fachbereich Chem., Univ. Kaiserslautern,
 Kaiserslautern, Fed. Rep. Ger.
 SOURCE: Justus Liebigs Annalen der Chemie (1974), (10), 1702-8
 CODEN: JLACBF; ISSN: 0075-4617
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI For diagram(s), see printed CA Issue.
 AB The diazocycloalkanones I (n = 3-5, 9, or 10) reacted with
 MeO2CC.tplbond.CCO2Me via pyrazolenine intermediates to give the bicyclic
 compds. II (R = R1 = CO2Me) (III), which was interpreted as a sigmatropic
 1,5-acyl shift. In the same way, RC.tplbond.CR1 (R = R1 = CN or CF3 or R
 = H, R1 = COMe or CO2Me) reacted with I (n = 4) to give the corresponding
 II. Alkaline hydrolysis of III gave the acids IV.
 IT 41482-72-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and hydrolysis)
 RN 41482-72-8 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepine-2,3-dicarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-
 , dimethyl ester (9CI) (CA INDEX NAME)




IT 55300-02-2P 55300-03-3P 55300-04-4P
 55300-06-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55300-02-2 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepine-2,3-dicarbonitrile, 5,6,7,8-tetrahydro-8-oxo-
 (9CI) (CA INDEX NAME)



10/531,111


RN 55300-03-3 CAPLUS

CN 8H-Pyrazolo[1,5-a]azepin-8-one, 4,5,6,7-tetrahydro-2,3-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 55300-04-4 CAPLUS

CN 8H-Pyrazolo[1,5-a]azepin-8-one, 2-acetyl-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 55300-06-6 CAPLUS


CN 4H-Pyrazolo[1,5-a]azepine-2-carboxylic acid, 5,6,7,8-tetrahydro-8-oxo-, methyl ester (9CI) (CA INDEX NAME)



Y L13 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1974:146070 CAPLUS
 DOCUMENT NUMBER: 80:146070
 ORIGINAL REFERENCE NO.: 80:23573a,23576a
 TITLE: Synthesis of substituted indazoles and pyrazoles from
 the 1,3-dipolar cyclo addition of α -diazo
 ketones
 AUTHOR(S): Rodina, L. L.; Bulusheva, V. V.; Ekimova, T. G.;
 Korobitsyna, I. K.
 CORPORATE SOURCE: Leningr. Gos. Univ. im. Zhdanova, Leningrad, USSR
 SOURCE: Zhurnal Organicheskoi Khimii (1974), 10(1), 55-9
 CODEN: ZORKAE; ISSN: 0514-7492
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB MeO2CC.tplbond.CCO2Me (I) cyclized with RCOCHN2 (R = Me, Et) in Et2O at
 0° to give the pyrazoles II. Analogously, α -
 diazocyclohexanone and α -diazocyclopentanone condensed with I to
 yield the pyrazoloazepine III and the pyrazolopyridine IV, resp.
 Hydrolysis of III and IV in refluxing H2O at pH 3-7 yielded the carboxylic
 acids V (n = 4, 3, resp.)
 IT 41482-72-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 41482-72-8 CAPLUS
 CN 4H-Pyrazolo[1,5-a]azepine-2,3-dicarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-
 , dimethyl ester (9CI) (CA INDEX NAME)



☒ L13 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1973:159513 CAPLUS
DOCUMENT NUMBER: 78:159513
ORIGINAL REFERENCE NO.: 78:25615a,25618a
TITLE: 1,3-Dipolar addition of cyclic diazo ketones to
alkynes and cyclopropenes. Synthesis of heterocyclic
compounds by [1,5]-acyl migration
AUTHOR(S): Franck-Neumann, Michel; Buchecker, Christiane
CORPORATE SOURCE: Inst. Chim., Univ. Louis Pasteur, Strasbourg, Fr.
SOURCE: Angewandte Chemie (1973), 85(6), 259-60
CODEN: ANCEAD; ISSN: 0044-8249
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Cyclic α -diazo ketones, e.g. α -diazocyclopentanone or
-hexanone (I), diazonorbornanone or -camphor, or 2-diazocholestan-3-one,
reacted with RC.tplbond.CR (R = CO₂Me, II) to give the pyrazolo derivs.
III (n = 1 or 2), IV (R₁ = H or Me, 63 and 73% yield), and V (61% yield),
resp., via the nonisolated spiran intermediates, e.g. VI. The reaction of
I with the very reactive 1,2-bis(methoxycarbonyl)-3,3-dimethylcyclopropene
instead of II stopped at the spiran stage.
IT 41482-72-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41482-72-8 CAPLUS
CN 4H-Pyrazolo[1,5-a]azepine-2,3-dicarboxylic acid, 5,6,7,8-tetrahydro-8-oxo-
, dimethyl ester (9CI) (CA INDEX NAME)



10/531,111

=> => d his

(FILE 'HOME' ENTERED AT 12:06:04 ON 09 NOV 2007)

FILE 'REGISTRY' ENTERED AT 12:06:46 ON 09 NOV 2007

L1 STRUCTURE UPLOADED
L2 6. S L1
L3 210 S L1 SSS FUL
L4 147 S L3 AND CAPLUS/LC
L5 63 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 12:07:42 ON 09 NOV 2007

L6 65 S L3

FILE 'REGISTRY' ENTERED AT 12:08:20 ON 09 NOV 2007

L7 22 S L3 AND NRS>2
L8 188 S L3 NOT L7
L9 147 S L3 AND NRS=1
L10 63 S L3 NOT L9
L11 86147 S 5-7/SZ
L12 51 S L3 AND L11

FILE 'CAPLUS' ENTERED AT 12:10:12 ON 09 NOV 2007

L13 14 S L12


FILE 'REGISTRY' ENTERED AT 12:15:33 ON 09 NOV 2007

L14 45 S L12 AND CAPLUS/LC
L15 6 S L12 NOT L14

=> d 1-6

10/531,111


☒ L15 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 344753-04-4 REGISTRY
ED Entered STN: 06 Jul 2001
CN 1H-Pyrazolo[1,5-a]azepine-1-propanoic acid, 2-benzoyl- β -ethoxy-3-phenyl-, methyl ester (CA INDEX NAME)
MF C27 H26 N2 O4
SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/531,111

☒ L15 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 157708-99-1 REGISTRY
ED Entered STN: 16 Sep 1994
CN Pyrazolo[1,5-a]azepin-9-ium (9CI) (CA INDEX NAME)
MF C8 H7 N2
CI RPS
SR CA Index Guide or Ring Systems Handbook




10/531,111

☒ L15 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 156894-20-1 REGISTRY
ED Entered STN: 10 Aug 1994
CN Pyrazolo[1,5-a]azepin-9-ium, 2-butyl-1,4,5,6,7,8-hexahydro-1-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)
MF C18 H22 Cl3 N2
CI COM
SR CA



10/531,111


☒ L15 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 42318-45-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Pyrazolo[1,5-a]azepine (9CI) (CA INDEX NAME)
MF C8 H8 N2
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/531,111


☒ L15 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 42119-90-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4H-Pyrazolo[1,5-a]azepine (9CI) (CA INDEX NAME)
MF C8 H8 N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/531,111

☒ L15 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 32921-73-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 8H-Pyrazolo[1,5-a]azepine (9CI) (CA INDEX NAME)
MF C8 H8 N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT